---
title: "Chemed Insider Makes a Bold Move With a High-Value Stock Sale"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288146533.md"
description: "Chemed director George Walsh sold 500 shares worth $218,915 on May 29, 2026. This follows an upbeat Q1 earnings call where management raised 2026 guidance due to strong VITAS hospice trends. However, analysts noted margin pressure at Roto-Rooter. TipRanks' AI Analyst rates CHE as 'Outperform,' citing healthy financials and positive outlook, though technicals are overbought."
datetime: "2026-05-30T02:11:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288146533.md)
  - [en](https://longbridge.com/en/news/288146533.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288146533.md)
generator: "portal-rs"
---

# Chemed Insider Makes a Bold Move With a High-Value Stock Sale

New insider activity at Chemed ( (CHE) ) has taken place on May 29, 2026.

### Memorial Day Sale – Claim 70% Off TipRanks

-   Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
-   Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

Director George Walsh has recently cashed out a portion of his holdings in Chemed, selling 500 shares of the company’s stock in a transaction valued at $218,915. This insider sale highlights a notable move by a member of Chemed’s board, as the trade converts a significant block of his equity stake into cash while providing investors with a clear, disclosed record of his latest activity in the stock.

**Recent Updates on CHE stock** 

Chemed’s stock reacted to its upbeat Q1 earnings call, where management raised 2026 revenue and EPS guidance mainly on stronger hospice trends at VITAS, including faster admissions growth, resilient margins, and a larger Florida Medicare cap cushion that eased prior regulatory concerns. Offsetting this, analysts noted ongoing margin pressure and higher marketing spend at Roto-Rooter, plus weather and pricing headwinds, leading to more cautious views even as overall earnings power improved.

**Spark’s Take on CHE Stock**

According to Spark, TipRanks’ AI Analyst, CHE is a Outperform.

The score is supported primarily by strong financial performance (healthy margins, low leverage, and strong free cash flow) and a generally positive earnings outlook led by VITAS and raised guidance. Technicals indicate an uptrend but are overbought, while valuation is reasonable but not cheap given the low dividend yield; governance sentiment is a modest drag due to the say-on-pay rejection.

To see Spark’s full report on CHE stock, click here. 

**More about Chemed**

**YTD Price Performance:** 3.08%

**Average Trading Volume:** 261,253

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $5.83B

### Related Stocks

- [CHE.US](https://longbridge.com/en/quote/CHE.US.md)

## Related News & Research

- [Chemed (NYSE:CHE) Posts Earnings Results](https://longbridge.com/en/news/294127496.md)
- [Chemed declares quarterly dividend of 70 cents a share](https://longbridge.com/en/news/295126359.md)
- [Chemed Corporation (NYSE:CHE) to Issue Dividend Increase - $0.70 Per Share](https://longbridge.com/en/news/295234954.md)
- [Chemed Corporation (NYSE:CHE) Given Consensus Rating of "Hold" by Analysts](https://longbridge.com/en/news/294342032.md)
- [Chemed Q2 revenue beats estimates, helped by VITAS segment growth](https://longbridge.com/en/news/294109919.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**